This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Natrajan, R. Articles by Jones, C. Search for Related Content PubMed PubMed Citation Articles by Natrajan, R. Articles by Jones, C.

Blastemal Expression of Type I Insulin-Like Growth Factor Receptor in Wilms' Tumors Is Driven by Increased Copy Number and Correlates with Relapse

¹ Paediatric Oncology, Institute of Cancer Research/Royal Marsden National Health Service Trust, Sutton, United Kingdom; ² The Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, London, United Kingdom; ³ Birmingham Children's Hospital, Birmingham, United Kingdom; ⁴ Department of Hematology/Oncology, St Jude Children's Research Hospital, Memphis, Tennessee; ⁵ Departments of Paediatrics and Oncology, University of Alberta, Edmonton, Alberta, Canada; and ⁶ University of Wales Medical School, Cardiff, United Kingdom

Requests for reprints: Chris Jones, Paediatric Oncology, Institute of Cancer Research, 15 Cotswold Road, Sutton, Surrey, SM2 5NG, United Kingdom. Phone: 44-20-8722-4416; Fax: 44-20-8722-4321; E-mail: chris.jones{at}icr.ac.uk.

Most Wilms' tumors are of low stage, favorable histology, and have a high likelihood of cure with current multimodal therapy. Despite this, there remains a group of patients whose tumors recur for whom intensive salvage regimens result in survival of only 50%. Fitting a Cox proportional hazards model to microarray-based comparative genomic hybridization (aCGH) data on 68 Wilms' tumor samples, we identified a significant correlation between increased copy number at chromosome 15q26.3 insulin-like growth factor I receptor (IGFIR) and tumor relapse (adjusted P = 0.014). Wilms' tumors (13%) exhibited a low-level gain corresponding to three to four copies of the gene by aCGH analysis, 9 of 10 of which exhibited high IGFIR mRNA levels. Although IGFIR protein expression was restricted to the epithelial cells of fetal kidney and Wilms' tumors in most cases, 12% of tumors were also found to express IGFIR in the blastemal compartment. Blastemal IGFIR protein expression was associated with an increased copy number and a shorter relapse-free survival time (P = 0.027, log-rank test). In addition to the membrane localization, IGFIR was localized to the perinuclear region of the blastemal cells in 6% of Wilms' tumors. These data provide evidence that an increase in IGFIR gene copy number results in aberrant expression in the blastemal compartment of some Wilms' tumors and is associated with an adverse outcome in these patients. These findings suggest the possibility of use of targeted agents in the therapy of these children. (Cancer Res 2006; 66(23): 11148-55)

This article has been cited by other articles:

				R. Vuononvirta, N. J. Sebire, B. Messahel, N. Perusinghe, J. S. Reis-Filho, K. Pritchard-Jones, G. M. Vujanic, and C. Jones Expression of Hepatocyte Growth Factor and Its Receptor Met in Wilms' Tumors and Nephrogenic Rests Reflects Their Roles in Kidney Development Clin. Cancer Res., April 15, 2009; 15(8): 2723 - 2730. [Abstract] [Full Text] [PDF]

				C.-C. Huang, S. Gadd, N. Breslow, C. Cutcliffe, S. T. Sredni, I. B. Helenowski, J. S. Dome, P. E. Grundy, D. M. Green, M. K. Fritsch, et al. Predicting Relapse in Favorable Histology Wilms Tumor Using Gene Expression Analysis: A Report from the Renal Tumor Committee of the Children's Oncology Group Clin. Cancer Res., March 1, 2009; 15(5): 1770 - 1778. [Abstract] [Full Text] [PDF]

				S. Y. Kim, J. A. Toretsky, D. Scher, and L. J. Helman The Role of IGF-1R in Pediatric Malignancies Oncologist, January 1, 2009; 14(1): 83 - 91. [Abstract] [Full Text] [PDF]

				R. Vuononvirta, N. J. Sebire, A. R. Dallosso, J. S. Reis-Filho, R. D. Williams, A. Mackay, K. Fenwick, A. Grigoriadis, A. Ashworth, K. Pritchard-Jones, et al. Perilobar Nephrogenic Rests Are Nonobligate Molecular Genetic Precursor Lesions of Insulin-Like Growth Factor-II-Associated Wilms Tumors Clin. Cancer Res., December 1, 2008; 14(23): 7635 - 7644. [Abstract] [Full Text] [PDF]

				C. Tarn, L. Rink, E. Merkel, D. Flieder, H. Pathak, D. Koumbi, J. R. Testa, B. Eisenberg, M. von Mehren, and A. K. Godwin Insulin-like growth factor 1 receptor is a potential therapeutic target for gastrointestinal stromal tumors PNAS, June 17, 2008; 105(24): 8387 - 8392. [Abstract] [Full Text] [PDF]